| Dr Russell James Kilpatrick, MD | |
|
1850 W Arlington Blvd, Greenville, NC 27834-5704 | |
| (252) 413-6740 | |
| Not Available |
| Full Name | Dr Russell James Kilpatrick |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 49 Years |
| Location | 1850 W Arlington Blvd, Greenville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568449080 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 21983 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera Mckennan Hospital & University Health Center | Sioux falls, SD | Hospital |
| Decatur County Hospital | Leon, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Avera Mckennan | 0345157103 | 848 |
| Decatur County Hospital | 9739085754 | 16 |
News Archive
The use of antibiotics to treat bacterial infections causes a continual and vicious cycle in which antibiotic treatment leads to the emergence and spread of resistant strains, forcing the use of additional drugs leading to further multi-drug resistance.
Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.
Rui Costa, principal investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciencia (IGC), in Portugal, is one of only 219 recipients of the prestigious European Research Council Starting grants, out of 2503 applicants for the 2009 edition of this flagship award scheme. The grant, totalling close to 1.6 million euro, for a period of five years, will allow Rui Costa's young research team to pursue their research into the neurological mechanisms underlying goal-directed decision making behaviour, versus habit-based responses.
Generex Biotechnology Corporation announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration Expanded Access Treatment Investigational New Drug Program for Generex Oral-lyn, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.
› Verified 3 days ago
| Entity Name | Avera Mckennan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003389206 PECOS PAC ID: 0345157103 Enrollment ID: O20031110000117 |
News Archive
The use of antibiotics to treat bacterial infections causes a continual and vicious cycle in which antibiotic treatment leads to the emergence and spread of resistant strains, forcing the use of additional drugs leading to further multi-drug resistance.
Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.
Rui Costa, principal investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciencia (IGC), in Portugal, is one of only 219 recipients of the prestigious European Research Council Starting grants, out of 2503 applicants for the 2009 edition of this flagship award scheme. The grant, totalling close to 1.6 million euro, for a period of five years, will allow Rui Costa's young research team to pursue their research into the neurological mechanisms underlying goal-directed decision making behaviour, versus habit-based responses.
Generex Biotechnology Corporation announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration Expanded Access Treatment Investigational New Drug Program for Generex Oral-lyn, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Russell James Kilpatrick, MD 1850 W Arlington Blvd, Greenville, NC 27834-5704 Ph: (252) 413-6740 | Dr Russell James Kilpatrick, MD 1850 W Arlington Blvd, Greenville, NC 27834-5704 Ph: (252) 413-6740 |
News Archive
The use of antibiotics to treat bacterial infections causes a continual and vicious cycle in which antibiotic treatment leads to the emergence and spread of resistant strains, forcing the use of additional drugs leading to further multi-drug resistance.
Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.
Rui Costa, principal investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciencia (IGC), in Portugal, is one of only 219 recipients of the prestigious European Research Council Starting grants, out of 2503 applicants for the 2009 edition of this flagship award scheme. The grant, totalling close to 1.6 million euro, for a period of five years, will allow Rui Costa's young research team to pursue their research into the neurological mechanisms underlying goal-directed decision making behaviour, versus habit-based responses.
Generex Biotechnology Corporation announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration Expanded Access Treatment Investigational New Drug Program for Generex Oral-lyn, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.
› Verified 3 days ago
Dr. Mary Helen Allen Hutchinson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 420 Spring Forest Rd, Greenville, NC 27834 Phone: 252-752-4124 Fax: 252-758-8954 | |
Dr. Drury L Armistead, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1850 W Arlington Blvd, Greenville, NC 27834 Phone: 252-413-6740 Fax: 252-752-6600 | |
Dr. Eric Richard Howell, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 420 Spring Forest Rd, Greenville, NC 27834 Phone: 252-752-4124 Fax: 252-758-8954 | |
Dr. Jennifer Marie Defazio, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 517 Moye Blvd, Greenville, NC 27834 Phone: 252-744-3109 Fax: 252-744-2096 | |
Dr. William A Burke, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 817 Moye Blvd Fl. 3, Ecu Physicians Dermetology Moye Medical Center #2, Greenville, NC 27834 Phone: 252-744-3109 Fax: 252-744-2096 | |
Dr. Austin Jeannine Newsome, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 420 Spring Forest Rd, Greenville, NC 27834 Phone: 252-752-4124 Fax: 252-752-6146 |